ADMA Biologics Believes It Can Resolve CRL Issues Quickly, Spring Review Possible

By |2018-12-28T10:31:02-05:00December 28th, 2018|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents|Tags: , , |

Shares of ADMA Biologics [NASDAQ:ADMA]  fell more than 45% on [...]